Board-certified urologist Bela Denes trained at Washington University in St. Louis, Missouri. With 25 years of clinical and academic experience Bela now leads the Genomic Health Medical Affairs team as the Senior Director of Urology. In an interview on this site he discusses the Oncotype DX Prostate Cancer Assay, one of the new tests using advanced genomic methods. This test examines the activity level of 17 genes from a biopsy sample and computes a score from 0 to 100, distinguishing aggressive prostate cancer from less threatening prostate cancer. The test results provide useful information for men considering or already following an active surveillance regimen, and for other patients as well.